AI is reshaping biotechnology in subtle but uneven ways. While discovery accelerates, clinical development and regulation remain stubbornly complex. The result is not a revolution, but a quiet, incremental shift that may redefine how biotech grows and collaborates in the years ahead.
The Promise and the Reality
The narrative around artificial intelligence in biotechnology tends toward extremes. On one side, breathless optimism: AI will compress drug discovery timelines from decades to months, predict clinical outcomes before a trial begins, and fundamentally rewrite the economics of bringing a therapy to market. On the other, scepticism: that the hype outpaces the science, and that the messy realities of biology resist neat computational solutions.
The truth, as usual, sits somewhere in the middle. AI is genuinely accelerating parts of the biotech value chain, particularly in target identification, molecular design, and preclinical screening. But its impact on the later, costlier, and more consequential stages of development remains far more modest.
Where AI Is Already Making a Difference
In early-stage discovery, the gains are real and measurable. Machine learning models can now screen billions of molecular combinations in silico, identifying candidates that would have taken traditional methods years to surface. Protein structure prediction, supercharged by tools like AlphaFold, has unlocked new avenues in target validation that were previously impractical.
For biotech companies, particularly smaller firms operating with constrained resources, this represents a genuine shift in what is possible. The cost of generating a credible lead candidate is falling, and the speed at which hypotheses can be tested has increased dramatically. This is not theoretical; companies across the sector are already building pipelines on this foundation.
The Stubborn Middle
Clinical development, however, tells a different story. Regulatory pathways are inherently conservative, and for good reason. The FDA, EMA, and other agencies are still working through how AI-generated evidence should be evaluated, validated, and trusted within existing frameworks. This is not a failure of imagination; it is a necessary process of building institutional confidence in fundamentally new approaches.
Manufacturing and supply chain present similar challenges. Biotech production, particularly for advanced therapies like cell and gene treatments, involves living systems with intrinsic variability. AI can optimise parameters and predict failures, but it cannot eliminate the biological complexity that makes these therapies both powerful and difficult to scale.
The Collaboration Imperative
What is becoming clear is that AI's value in biotech is not as a standalone force, but as an enabler of better collaboration. The companies seeing the most meaningful results are those combining AI capabilities with deep domain expertise, pairing computational power with biological intuition rather than treating them as substitutes.
This has implications for how the sector organises itself. Partnerships between AI-native companies and established biotech firms are likely to become more common, and more necessary. The winners will not be those with the best algorithms alone, but those who can integrate computational insights into the full complexity of drug development and commercialisation.
Looking Ahead
The disruption AI brings to biotech is real, but it is quieter and more uneven than headlines suggest. It is accelerating discovery while leaving clinical development and regulation largely intact, at least for now. The companies that navigate this landscape successfully will be those that resist the temptation to overstate what AI can do today, while investing seriously in what it might enable tomorrow.
The march is uneven. But it is a march nonetheless.